Which type of rejection reaction does belumosudil have a significant effect on and its clinical evaluation?

Belumosudil is a selective Rho-related protein kinase2( span>ROCK2) inhibitors are mainly used to treat chronic graft-versus-host disease (cGVHD), a complex immune rejection reaction. cGVHD is one of the most common serious complications after hematopoietic stem cell transplantation, often leading to multiple organ damage and a significant decrease in the patient's quality of life. Besudil relieves the symptoms of chronic GVHD by regulating the function of immune cells and inhibiting inflammatory responses.

Clinical studies have shown that Besudil has shown significant efficacy in the treatment of cGVHD patients who are ineffective or resistant to previous treatments. In one of its pivotal phase II clinical trials, the overall response rate in the besudil treatment group reached 74%, with some patients achieving complete remission. In addition, besudil can significantly improve patients' symptom scores and improve their quality of life. Compared with traditional immunosuppressants, besudil is better tolerated and has relatively mild adverse reactions.

Besudil affects the immune regulatory network by inhibitingROCK2, reducing the release of pro-inflammatory cytokines and promoting the establishment of an immune tolerance environment. This unique mechanism of action gives it a differentiated advantage in the treatment of chronic GVHD. Its efficacy has been recognized by the FDA and it was approved in 2021 for the treatment of relapsed or refractory chronic GVHD, becoming an important innovative drug in this field.

Overall, besudil brings new treatment hope to patients with chronic graft-versus-host disease. Its remarkable efficacy and good safety profile make it a clinically important choice. In the future, with the accumulation of more clinical data and application promotion, besudil is expected to improve the prognosis of more patients with cGVHD and improve their overall quality of life.

Reference materials:https://www.drugs.com/